Request a Quote

GSK Comirnaty Patent Ruling: UPC Ties a Wide Injunction to Final Validity

Ankit Saxena •November 17, 2026 •5 min read
GSK Comirnaty Patent Ruling: UPC Ties a Wide Injunction to Final Validity

In the GSK Comirnaty patent ruling of 10 November 2026, the Unified Patent Court (UPC) held that Comirnaty, the COVID-19 vaccine sold by Pfizer and BioNTech, falls within GSK’s patent EP 2 590 626. The patent covers liposomes for delivering ribonucleic acid (RNA). The Hague Local Division granted an injunction across the European Patent Convention (EPC) states where the patent is in force, except Ireland and the United Kingdom (UK). The order takes effect only once validity is finally decided.

The ruling matters because it pairs a wide injunction with a remedy designed to push the parties towards a licence.

What happened

GSK Biologicals brought the infringement action (UPC_CFI_620/2025) against Pfizer and BioNTech entities, which counterclaimed for revocation. According to a case summary by Dhenne Avocats, the panel upheld claims 1, 2, 3, 6, 10 and 12 and found them infringed. It held claim 13, which claims a medical use, invalid because the patent did not disclose it sufficiently. JUVE Patent reports that the remaining claims withstood all 5 invalidity attacks.

The remedy is the notable part. GSK itself asked for a deferral, and the court agreed. The injunction takes effect only after a final decision on validity, and then only if no licence is agreed within 3 months. Both sources describe the court treating GSK as a patentee seeking money rather than market exclusivity. For non-UPC countries, the order also depends on national courts not finding the patent invalid.

The defendants must provide sales information back to 1 January 2020 and make a provisional payment of EUR 2 million, as reported. JUVE Patent puts the value of the case at EUR 50 million. According to JUVE Patent, Pfizer and BioNTech can appeal and are pursuing revocation actions in the UK and Ireland. GSK has 2 further patents, EP 4 226 941 and EP 4 066 856, pending before the same division.

GSK also sued both companies in Delaware in April 2024, as Reuters reported at the time.

Not the first European win against Comirnaty

Moderna followed a similar path with its patent EP 3 590 949. On 1 August 2025, the Court of Appeal of England and Wales dismissed an appeal on validity, leaving in place a ruling that the patent was valid and infringed by Comirnaty ([2025] EWCA Civ 1032). In Germany, a regional court had found infringement and confirmed Moderna’s right to damages, as Moderna noted with an appeal pending. JUVE Patent dates that Düsseldorf ruling to 5 March 2025.

Both wins now look fragile. Moderna’s quarterly report for the period to 30 September 2026 states that a Technical Board of Appeal of the European Patent Office (EPO) revoked EP 3 590 949 in September 2026. Moderna’s cases in Belgium, Ireland and the Netherlands were dismissed as a result, while its German and UK proceedings await the written decision.

The contrast shows the value of a cautious remedy. A central EPO revocation can overtake national findings of validity in every designated state. In Synoptic IP’s reading, tying an injunction to the final validity outcome reduces the risk of ordering a vaccine off the market on a patent that later falls.

The wider picture in mRNA patents

Several high-profile messenger RNA (mRNA) patent disputes of the last 2 years have ended in payments and licences rather than exclusion.

On 8 August 2025, CureVac and GSK announced a settlement of their US litigation with BioNTech and Pfizer. It included USD 740 million in payments, single-digit royalties on future US sales and a non-exclusive licence for COVID-19 and influenza mRNA products. BioNTech then completed its acquisition of CureVac on 18 December 2025.

On 3 March 2026, Moderna settled its worldwide lipid nanoparticle dispute with Arbutus and Genevant for USD 950 million, according to its quarterly report. Up to USD 1.3 billion more depends on a pending appeal. Then, on 28 October 2026, Moderna and GSK settled their US and European disputes with infectious disease cross-licences and no payments, a deal covered in Synoptic IP’s analysis of the Moderna GSK settlement.

The disputes span both the mRNA molecule and its delivery, and lipid nanoparticle patents drew the single largest payment.

What it means for vaccine developers and patent owners

For implementers, the decision confirms that a single UPC action can reach most of Europe, including EPC states outside the UPC. A deferred injunction is still an injunction: once validity is settled, the window to agree terms is 3 months.

For patent owners in drug delivery, this case suggests that formulation claims with defined features can withstand repeated validity attacks, while a medical-use claim may need firmer support in the description.

For both sides, validity is now the deciding question. Companies facing formulation patents may benefit from testing them early with an invalidity search that covers journal articles and conference material as well as patent documents. Companies launching new mRNA or lipid products may wish to consider freedom-to-operate reviews against older liposome and lipid nanoparticle estates, which remain enforced.

Synoptic IP’s view

Synoptic IP’s view is that the Hague decision offers a sensible template for disputes over platform technologies. The view rests on 3 facts. First, the court found infringement and gave GSK real bargaining power through a broad injunction and a provisional payment.

Second, the order waits for a final validity outcome, and the revocation of EP 3 590 949 shows why that matters. Third, the 3-month licence window matches what the market has done: CureVac, Arbutus and GSK have each resolved disputes through payments or licences.

The strongest counter-argument is that deferral weakens the injunction. A patent owner who wins on infringement must wait, possibly for years, while the product stays on sale. Deferral may also reduce the incentive to resolve validity challenges quickly.

That concern is real, and it weighs more for an owner that competes in the market. Where the owner mainly seeks royalties, as reported here, a conditional order protects that interest and avoids an injunction resting on a patent that later falls. The approach may fit less well where exclusivity, not money, is what the owner needs.

Companies assessing exposure to lipid or liposome delivery patents can start with our patent invalidity search or freedom-to-operate search services.

This article is commentary and opinion based on public reports as of 18 November 2026 and is not legal advice.

Have a search on your docket?

One senior specialist runs your search end to end. Tell us the matter and you’ll have scope, fee and a delivery date back.

Request a Quote
← All articles